898 reports of this reaction
3.0% of all DORNASE ALFA reports
#9 most reported adverse reaction
DYSPNOEA is the #9 most commonly reported adverse reaction for DORNASE ALFA, manufactured by Genentech, Inc.. There are 898 FDA adverse event reports linking DORNASE ALFA to DYSPNOEA. This represents approximately 3.0% of all 29,815 adverse event reports for this drug.
Patients taking DORNASE ALFA who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for DORNASE ALFA, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for DORNASE ALFA:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 898 FDA reports for DORNASE ALFA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.0% of all adverse event reports for DORNASE ALFA, making it a notable side effect.
If you experience dyspnoea while taking DORNASE ALFA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.